CD95/Fas suppresses NF-κB activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism

被引:17
|
作者
Guegan, Jean-Philippe [1 ]
Pollet, Justine [2 ]
Ginestier, Christophe [3 ]
Charafe-Jauffret, Emmanuelle [3 ]
Peter, Marcus E. [4 ]
Legembre, Patrick [5 ]
机构
[1] Explicyte, Cours Argonne, F-33000 Bordeaux, France
[2] Univ Limoges, Technol Core Facil BISCEm, CHU Limoges, US042,Inserm,UMS CNRS 2015, Limoges, France
[3] Aix Marseille Univ, CNRS, INSERM, Inst Paoli Calmettes,CRCM Mol Oncol Equipe Labell, Marseille, France
[4] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA
[5] Univ Limoges, UMR CNRS 7276, CRIBL, INSERM 1262, Limoges, France
关键词
SIGNALING PATHWAY; NITRIC-OXIDE; SOMATIC MUTATIONS; FAS LIGAND; PROTEIN; EXPRESSION; GENE; RECEPTOR; CELLS; APOPTOSIS;
D O I
10.1016/j.isci.2021.103538
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
CD95 expression is preserved in triple-negative breast cancers (TNBCs), and CD95 loss in these cells triggers the induction of a pro-inflammatory program, promoting the recruitment of cytotoxic NK cells impairing tumor growth. Herein, we identify a novel interaction partner of CD95, Kip1 ubiquitination-promoting complex protein 2 (KPC2), using an unbiased proteomic approach. Independextly of CD95L, CD95/KPC2 interaction contributes to the partial degradation of p105 (NF-kappa B1) and the subsequent generation of p50 homodimers, which transcriptionally represses NF-kappa B-driven gene expression. Mechanistically, KPC2 interacts with the C-terminal region of CD95 and serves as an adaptor to recruit ReIA (p65) and KPC1, which acts as E3 ligase promoting the degradation of p105 into p50. Loss of CD95 in TNBC cells releases KPC2, limiting the formation of the NF-kappa B inhibitory homodimer complex (p50/p50), promoting NF-kappa B activation and the production of pro-inflammetory cytokines, which might contribute to remodeling the immune landscape in TNBC cells.
引用
收藏
页数:21
相关论文
共 50 条
  • [41] Effect of track CD14/TLR4 on the proliferation of glioblastomas induced for the activation of the CD95/CD95L way
    Sarrazy, V
    Billet, F.
    Jauberteau, M. O.
    Desmouliere, A.
    BULLETIN DU CANCER, 2009, 96 : S30 - S30
  • [42] Induction of apoptosis and activation of NF-κB by CD95 require different signalling thresholds
    Legembre, P
    Barnhart, BC
    Zheng, LX
    Vijayan, S
    Straus, SE
    Puck, J
    Dale, JK
    Lenardo, M
    Peter, ME
    EMBO REPORTS, 2004, 5 (11) : 1084 - 1089
  • [43] Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma
    Blaes, Jonas
    Thome, Carina M.
    Pfenning, Philipp-Niclas
    Ruebmann, Petra
    Sahm, Felix
    Wick, Antje
    Bunse, Theresa
    Schmenger, Torsten
    Sykora, Jaromir
    von Deimling, Andreas
    Wiestler, Benedikt
    Merz, Christian
    Jugold, Manfred
    Haberkorn, Uwe
    Abdollahi, Amir
    Debus, Juergen
    Gieffers, Christian
    Kunz, Claudia
    Bendszus, Martin
    Kluge, Michael
    Platten, Michael
    Fricke, Harald
    Wick, Wolfgang
    Lemke, Dieter
    MOLECULAR CANCER RESEARCH, 2018, 16 (05) : 767 - 776
  • [44] Fas(CD95) and FasL(CD95L) expression in cutaneous and non-cutaneous CD30+ anaplastic large cell lymphomas (ALCL) reveals quantitative differences in antigen expression.
    Sigel, JE
    Hsi, ED
    LABORATORY INVESTIGATION, 1999, 79 (01) : 145A - 145A
  • [45] Reactive astrocytes upregulate Fas (CD95) and Fas ligand (CD95L) expression but do not undergo programmed cell death during the course of anterograde degeneration
    Bechmann, I
    Lossau, S
    Steiner, B
    Mor, G
    Gimsa, U
    Nitsch, R
    GLIA, 2000, 32 (01) : 25 - 41
  • [46] Effect of the CD14/TLR4 pathway on glioblastoma cell proliferation induced by CD95/CD95L pathway activation
    Sarrazy, V.
    Billet, F.
    Jauberteau, M. O.
    Desmouliere, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2009, 23 : 78 - 78
  • [47] Fas ligand (FasL, CD95L, APO-1L) expression in murine mast cells
    Wagelie-Steffen, AL
    Hartmann, K
    Vliagoftis, H
    Metcalfe, DD
    IMMUNOLOGY, 1998, 94 (04) : 569 - 574
  • [48] NFκB mediates FAS(CD95) upregulation in a model of adenoviral hepatitis.
    Zender, L
    Kuehnel, F
    Paul, Y
    Trautwein, C
    Kubicka, S
    Manns, MP
    HEPATOLOGY, 1999, 30 (04) : 387A - 387A
  • [49] CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants
    Eberle, J
    Fecker, LF
    Hossini, AM
    Wieder, T
    Daniel, PT
    Orfanos, CE
    Geilen, CC
    ONCOGENE, 2003, 22 (57) : 9131 - 9141
  • [50] CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants
    Jürgen Eberle
    Lothar F Fecker
    Amir M Hossini
    Thomas Wieder
    Peter T Daniel
    Constantin E Orfanos
    Christoph C Geilen
    Oncogene, 2003, 22 : 9131 - 9141